Jaktinib Hydrochloride Cream For Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study includes a dose escalation part and a dose extension part.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Criteria

Inclusion Criteria:

• 18~ 65 years old (including boundary value), gender is not limited;

• Have a clinical diagnosis of atopic dermatitis;

• Have a PGA(Physician's Global Assessment) score of 2 (mild) or 3 (moderate) at baseline;

• The total area of atopic dermatitis is about 10%~20% of the total area of the body surface at baseline.

Exclusion Criteria:

• Evidence of certain skin conditions/infections at baseline;

• Have certain laboratory abnormalities at baseline;

• Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception;

• Other conditions that the investigators considered inappropriate to participate in the trial.